Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Stockholders Equity of $5.28 million for the year ending 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +29.7% in Stockholders Equity from 2024 to 2025.
- This data is from ADIAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$1.31 million | Q2 2018: -$1.29 million | Q3 2018: $4.93 million | Q1 2019: $11.73 million | Q2 2019: $10.06 million | Q3 2019: $8.73 million | Q1 2020: $5.55 million | Q2 2020: $8.79 million | Q3 2020: $7.09 million | Q1 2021: $5.62 million | Q2 2021: $4.83 million | Q3 2021: $7.20 million | Q1 2022: $10.71 million | Q2 2022: $7.96 million | Q3 2022: $5.41 million | Q1 2023: $1.44 million | Q2 2023: $3.32 million | Q3 2023: $2.34 million | Q1 2024: $6.12 million | Q2 2024: $4.28 million | Q3 2024: $5.88 million | Q1 2025: $2.13 million | Q2 2025: $5.59 million | Q3 2025: $4.51 million.
- Over the full 10 years of available data (2016 to 2025), ADIAL PHARMACEUTICALS, INC.'s Stockholders Equity has grown by 5,198.4%.
- Historical annual values: Fiscal year 2025: $5.28 million | Fiscal year 2024: $4.07 million | Fiscal year 2023: $4.08 million | Fiscal year 2022: $3.28 million | Fiscal year 2021: $3.51 million | Fiscal year 2020: $3.99 million | Fiscal year 2019: $7.14 million | Fiscal year 2018: $4.44 million | Fiscal year 2017: -$997.6 thousand | Fiscal year 2016: -$103.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: